KAYTUS
14.5.2024 09:01:36 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, has unveiled MotusAI, an AI development platform now accessible for trial worldwide. MotusAI is tailored for deep learning and AI development, integrating GPU and data resources alongside AI development environments to streamline computing resource allocation, task orchestration, and centralized management. It accelerates training data and manages AI model development workflows seamlessly. This platform drastically reduces resource investment, boosts development efficiency, elevates cluster computing power utilization to over 70%, and significantly enhance in large-scale training task scheduling performance.
Streamline AI Development for Cost-Effectiveness and Efficiency
The rapid expansion of enterprise AI business and AI model development brings forth challenges including low computing efficiency, complexity in model development, varied requirements for task orchestration across different scenarios, and unstable computing resources. Ensuring efficient, flexible, and stable operation of AI business is critical for enterprises to consistently derive business insights, generate revenue, and maintain competitiveness.
Optimize Resource Management for Maximum Computing Power
MotusAI efficiently allocates resources and workloads by implementing intelligent and flexible GPU scheduling. It caters to diverse AI workload demands for computing power by dynamically allocating GPU resources based on demand. With multi-dimensional and dynamic GPU resource allocation, including fine-grained GPU scheduling and support for Multi-Instance GPU (MIG), MotusAI effectively meets computing power requirements across various scenarios such as model development, debugging, and training.
Streamline Task Orchestration for Versatile Support of Various Scenario
MotusAI has revolutionized cloud-native scheduling systems. Its scheduler surpasses the community version by dramatically improving the scheduling performance of large-scale POD tasks. MotusAI achieves rapid startup and environment readiness for hundreds of PODs, boasting a five times increase in throughput and a five times decrease in latency compared to the community scheduler. This ensures efficient scheduling and utilization of computing resources for large-scale training. Moreover, MotusAI enables dynamic scaling of AI workloads for both training and inference services, supporting burst tasks and fulfilling diverse scheduling needs across various scenarios.
MotusAI empowers users to maximize computing resources, spanning from fine-grained division of single-card multiple instances to large-scale parallel computing across multiple machines and cards. By integrating features like computing power pooling, dynamic scaling, and GPU single-card reuse, MotusAI significantly enhances computing power utilization, achieving an average utilization rate of over 70%. Furthermore, it enhances computing efficiency by leveraging cluster topology awareness and optimizing network communication.
Data Transfer Acceleration for Three Times Efficiency Improvement
MotusAI excels in data transfer acceleration through innovative features such as supporting local loading and computing of remote data, which eliminates delays caused by network I/O during computation. Utilizing strategies like "zero-copy" data transfer, multi-threaded retrieval, incremental data updates, and affinity scheduling, MotusAI significantly reduces data caching cycles. These enhancements greatly improve AI development and training efficiency, resulting in 2-3 times boost in model efficiency during data training.
Reliable, and Automatically Fault-Tolerant Platform
MotusAI supports performance monitoring and alerts for computing resources, providing real-time status updates for core platform services. It employs sandbox isolation mechanisms for data with higher security levels. In case of resource failures or abnormalities, MotusAI automatically initiates fault tolerance processes to ensure the quickest possible recovery during interrupted training tasks. This approach reduces fault handling time by over 90%, on average.
Comprehensive Management of AI Model Development in One Integrated Solution
MotusAI accelerates AI development and supports every stage of large model development. From managing data samples and software stacks to designing model architectures, debugging code, training models, tuning parameters, and conducting evaluation testing, MotusAI offers a complete platform. It integrates popular development frameworks like PyTorch and TensorFlow, along with distributed training frameworks such as Megatron and DeepSpeed.
Moreover, MotusAI enables comprehensive lifecycle management of AI inferencing services, including offline and online testing, A/B testing, rolling release, service orchestration, and service decommissioning. These features collectively enhance the business value of AI technology, fostering continuous business growth.
Additionally, MotusAI provides an integrated visual management and operation interface that covers computing, networking, storage, and application resources. Operational staff can comprehensively manage, monitor, and evaluate the overall platform operation status through a single interface.
Free Trial Available
MotusAI is now available worldwide for a trial period, offering free remote access for one month, along with testing, training, and support. Users can also opt for local deployment using their own devices and environment, with local deployment testing support from KAYTUS. For more information1 and to register2, please visit Link1, Link2.
About KAYTUS
KAYTUS is a premier provider of IT infrastructure products and solutions, delivering a suite of cutting-edge, open, and environmentally friendly infrastructure solutions for cloud, AI, edge computing, and other emerging technologies. With a customer-centric approach, KAYTUS adapts flexibly to user needs through its agile business model. Learn more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513665403/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
